NasdaqGM - Nasdaq Real Time Price USD
Veracyte, Inc. (VCYT)
At close: November 15 at 4:00 PM EST
After hours: November 15 at 4:09 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
425,331.00
361,051.00
296,536.00
219,514.00
117,483.00
Cost of Revenue
122,688.00
112,903.00
101,582.00
74,400.00
41,455.00
Gross Profit
302,643.00
248,148.00
194,954.00
145,114.00
76,028.00
Operating Expense
291,646.00
265,023.00
230,294.00
225,482.00
111,417.00
Operating Income
10,997.00
-16,875.00
-35,340.00
-80,368.00
-35,389.00
Net Non Operating Interest Income Expense
11,115.00
7,329.00
1,774.00
-106.00
365.00
Other Income Expense
-30,283.00
-67,066.00
-2,861.00
-1,175.00
115.00
Pretax Income
-8,171.00
-76,612.00
-36,427.00
-81,649.00
-34,909.00
Tax Provision
1,097.00
-2,208.00
133.00
-6,086.00
--
Net Income Common Stockholders
-9,268.00
-74,404.00
-36,560.00
-75,563.00
-34,909.00
Diluted NI Available to Com Stockholders
-9,268.00
-74,404.00
-36,560.00
-75,563.00
-34,909.00
Basic EPS
-0.13
-1.02
-0.51
-1.11
-0.66
Diluted EPS
-0.13
-1.02
-0.51
-1.11
-0.66
Basic Average Shares
75,358.51
72,644.49
71,549.20
67,890.33
53,239.23
Diluted Average Shares
76,282.96
72,644.49
71,549.20
67,890.33
53,239.23
Total Operating Income as Reported
-23,540.00
-85,795.00
-41,081.00
-81,903.00
-35,389.00
Rent Expense Supplemental
9,957.00
8,112.00
5,816.00
5,055.00
2,671.00
Total Expenses
414,334.00
377,926.00
331,876.00
299,882.00
152,872.00
Net Income from Continuing & Discontinued Operation
-9,268.00
-74,404.00
-36,560.00
-75,563.00
-34,909.00
Normalized Income
14,853.86
-8,727.02
-34,094.41
-74,562.58
-34,965.00
Interest Income
11,119.00
7,344.00
1,972.00
135.00
594.00
Interest Expense
4.00
15.00
198.00
241.00
229.00
Net Interest Income
11,115.00
7,329.00
1,774.00
-106.00
365.00
EBIT
-8,167.00
-76,597.00
-36,229.00
-81,408.00
-34,680.00
EBITDA
17,240.00
-49,409.00
-10,301.00
-61,815.00
-26,736.00
Reconciled Cost of Revenue
124,553.00
109,772.00
99,253.00
70,788.00
38,606.00
Reconciled Depreciation
23,542.00
27,188.00
25,928.00
19,593.00
7,944.00
Net Income from Continuing Operation Net Minority Interest
-9,268.00
-74,404.00
-36,560.00
-75,563.00
-34,909.00
Total Unusual Items Excluding Goodwill
-30,534.00
-67,626.00
-3,121.00
-1,081.00
56.00
Total Unusual Items
-30,534.00
-67,626.00
-3,121.00
-1,081.00
56.00
Normalized EBITDA
47,774.00
18,217.00
-7,180.00
-60,734.00
-26,792.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-6,412.14
-1,949.02
-655.41
-80.58
--
12/31/2020 - 10/30/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CDNA CareDx, Inc
21.17
-1.76%
TWST Twist Bioscience Corporation
36.89
-5.31%
NEO NeoGenomics, Inc.
15.04
-4.75%
GH Guardant Health, Inc.
29.11
-3.64%
MYGN Myriad Genetics, Inc.
15.25
-2.74%
NTRA Natera, Inc.
146.06
-3.34%
PSNL Personalis, Inc.
3.8900
-9.53%
RDNT RadNet, Inc.
79.58
-1.83%
CSTL Castle Biosciences, Inc.
28.10
-8.86%
EXAS Exact Sciences Corporation
49.33
-3.14%